Mark Diamond became the CEO of Antisense Therapeutics Limited (ASX:ANP) in 2001. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the business demonstrates. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.
How Does Mark Diamond's Compensation Compare With Similar Sized Companies?
Our data indicates that Antisense Therapeutics Limited is worth AU$34m, and total annual CEO compensation was reported as AU$446k for the year to June 2019. While we always look at total compensation first, we note that the salary component is less, at AU$392k. We took a group of companies with market capitalizations below AU$296m, and calculated the median CEO total compensation to be AU$384k.
So Mark Diamond receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.
You can see a visual representation of the CEO compensation at Antisense Therapeutics, below.
Is Antisense Therapeutics Limited Growing?
Over the last three years Antisense Therapeutics Limited has grown its earnings per share (EPS) by an average of 17% per year (using a line of best fit). In the last year, its revenue is up 115%.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Although we don't have analyst forecasts you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
Has Antisense Therapeutics Limited Been A Good Investment?
I think that the total shareholder return of 83%, over three years, would leave most Antisense Therapeutics Limited shareholders smiling. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.
Mark Diamond is paid around what is normal the leaders of comparable size companies.
Shareholders would surely be happy to see that shareholder returns have been great, and the earnings per share are up. Although the pay is a normal amount, some shareholders probably consider it fair or modest, given the good performance of the stock. Shareholders may want to check for free if Antisense Therapeutics insiders are buying or selling shares.
If you want to buy a stock that is better than Antisense Therapeutics, this free list of high return, low debt companies is a great place to look.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.